NCT07081698

Brief Summary

The objective is to investigate the effect of walnuts on gut microbiota, inflammatory markers, atopic dermatitis status, and indices of allergy outcomes in breastfed infants during early complementary feeding. The three primary aims include: Aim 1: Evaluate the effect of walnut consumption on gut microbiota structure and function, inflammation, atopic dermatitis, and allergy outcomes. Aim 2: Evaluate the impact of walnut consumption on infant growth trajectories and risk of overweight. Aim 3 (exploratory): Identify walnut-specific food signatures that are associated with gut microbiota and immunity biomarkers using a novel nutri-metabolomics technique.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for not_applicable

Timeline
20mo left

Started May 2025

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress37%
May 2025Dec 2027

First Submitted

Initial submission to the registry

February 27, 2025

Completed
3 months until next milestone

Study Start

First participant enrolled

May 18, 2025

Completed
2 months until next milestone

First Posted

Study publicly available on registry

July 23, 2025

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2027

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Last Updated

July 23, 2025

Status Verified

July 1, 2025

Enrollment Period

2.5 years

First QC Date

February 27, 2025

Last Update Submit

July 16, 2025

Conditions

Keywords

WalnutMicrobiomeInfantPediatricNutritionHealth

Outcome Measures

Primary Outcomes (11)

  • Gut Microbiome Composition Analyzed using 16S rRNA Amplicon Sequencing

    16S rRNA amplicon sequencing is used to profile taxonomic makeup of fecal specimens. Within the gut microbiome composition, microbial diversity will be summarized using common ecological measures (Good's coverage, Sobs, and Shannon alpha diversity).

    Over 7 months

  • Infant Growth (Length)

    Measured in cm

    Over 7 months

  • Infant Growth (Weight)

    Measured in kg

    Over 7 months

  • Dietary Intake

    3 day dietary recall with results generated by NDSR software

    Over 7 months

  • IL-33 (Interleukin-33)

    Measured in pg/mL

    Over 7 months

  • IL-6 (Interleukin-6)

    Measure in pg/mL

    Over 7 months

  • IL-8 (Interleukin-8)

    Measured in pg/mL

    Over 7 months

  • IL-13 (Interleukin-13)

    Measured in pg/mL

    Over 7 months

  • TGF-b (Transforming growth factor beta)

    Measured in ng/ml.

    Over 7 months

  • IL-4 (Interleukin-4)

    Measured in pg/mL

    Over 7 months

  • IL-10 (Interleukin 10)

    Measured in pg/mL

    Over 7 months

Secondary Outcomes (1)

  • Walnut-Specific Food Signatures (Compounds) as Assessed by Metabolomics Analysis

    Over 7 months

Study Arms (2)

The walnut group

EXPERIMENTAL

The intervention group will provide 10g of walnuts daily to their infant for 7 months.

Other: Infant walnut intake

Control Group

NO INTERVENTION

The control group will be asked to limit walnuts and tree nuts.

Interventions

The intervention group will receive walnuts at 10 g/day, and the control group will be advised to avoid walnuts/tree nuts during the intervention. The purpose of this research is to learn more about how walnuts as a first food in infants impact immunity and the development of bacteria living in your baby's gut.

The walnut group

Eligibility Criteria

Age5 Months - 5 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Full term: gestational age ≥ 37 weeks
  • Generally healthy without conditions that would affect normal growth
  • No significant consumption of complementary food (e.g., no more than 1 oz of solid foods per week)
  • Exclusively breastfed (\< 2 weeks of cumulative formula exposure)

You may not qualify if:

  • Adults unable to consent
  • Pregnant women
  • Prisoners

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Food Science and Human Nutrition Clinical Research Laboratory

Fort Collins, Colorado, 80523, United States

RECRUITING

Study Officials

  • Minghua Tang, Phd

    Colorado State University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Nathan Campbell, MS

CONTACT

Kinzie Matzeller, MS RDNCLC

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 27, 2025

First Posted

July 23, 2025

Study Start

May 18, 2025

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

December 31, 2027

Last Updated

July 23, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will not share

Locations